The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA.

Journal

Rhinology
ISSN: 0300-0729
Titre abrégé: Rhinology
Pays: Netherlands
ID NLM: 0347242

Informations de publication

Date de publication:
26 Sep 2024
Historique:
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact of comorbid upper and lower airway disease and blood eosinophil count (BEC) on sleep-/fatigue-related outcomes in CRSwNP. This was an analysis of the Phase III SYNAPSE and MUSCA (NCT03085797/NCT02281318) trials of mepolizumab in patients with severe CRSwNP and severe asthma, respectively. Endpoints included change from baseline in 22-item Sino-Nasal Outcome Test (SNOT-22) sleep and fatigue domains (SYNAPSE: Weeks 24 and 52; MUSCA: Week 24) in the overall populations and post hoc subgroups (SYNAPSE: comorbid asthma, comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease [N-ERD] and BEC [.

Sections du résumé

BACKGROUND BACKGROUND
The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact of comorbid upper and lower airway disease and blood eosinophil count (BEC) on sleep-/fatigue-related outcomes in CRSwNP.
METHODS METHODS
This was an analysis of the Phase III SYNAPSE and MUSCA (NCT03085797/NCT02281318) trials of mepolizumab in patients with severe CRSwNP and severe asthma, respectively. Endpoints included change from baseline in 22-item Sino-Nasal Outcome Test (SNOT-22) sleep and fatigue domains (SYNAPSE: Weeks 24 and 52; MUSCA: Week 24) in the overall populations and post hoc subgroups (SYNAPSE: comorbid asthma, comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease [N-ERD] and BEC [.

Identifiants

DOI: 10.4193/Rhin24.021 PMID: 39323188
pubmed: 39323188
pii: 3214
doi: 10.4193/Rhin24.021
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

J Mullol (J)

Department of Otorhinolaryngology, Hospital Clínic Barcelona, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.

W J Fokkens (WJ)

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, the Netherlands.

S G Smith (SG)

Clinical Sciences - Respiratory, GSK, Durham, NC, USA.

T Keeley (T)

Respiratory Patient Centered Outcomes, Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, UK.

L Zhang (L)

Respiratory Marketed Products Statistics, GSK, Warren, NJ, USA.

P Howarth (P)

Global Medical Affairs, GSK, Brentford, Middlesex, UK.

R H Chan (RH)

Respiratory Patient Centered Outcomes, Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, UK.

C Bachert (C)

Department of Otorhinolaryngology - Head and Neck Surgery, University Hospital of Münster, Münster, Germany.
Department of Otorhinolaryngology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

Classifications MeSH